triple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nametriple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences)
Drug Alias Nameanti-CD19 CAR T-cell therapy secreting PD-1Ab21 fusion protein (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences)PD-1Ab21-CD19CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocytes stimulantsInterleukin-21 stimulants +[5] 
TargetsInterleukin-21B-lymphocyte antigen CD19Programmed cell death protein 1
Therapy Area/IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalCD (Suzhou) Biopharma Co LtdChinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A